WO2000067790A1 - Verfahren zur behandlung von tnf-rezeptor typ-2 vermittelten krankheiten - Google Patents
Verfahren zur behandlung von tnf-rezeptor typ-2 vermittelten krankheiten Download PDFInfo
- Publication number
- WO2000067790A1 WO2000067790A1 PCT/EP2000/003866 EP0003866W WO0067790A1 WO 2000067790 A1 WO2000067790 A1 WO 2000067790A1 EP 0003866 W EP0003866 W EP 0003866W WO 0067790 A1 WO0067790 A1 WO 0067790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substances
- p75tnfric
- tnf
- use according
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- TNF-ä Human tumor necrosis factor alpha
- TNF-ä is a membrane-bound polypeptide precursor (26kDa), which is processed into a soluble form (17 kDa) by peptide cleavage. This soluble form trimerizes to mature bioactive TNF-a homotrimer (52 kDa).
- suitable substances for the use according to the invention are those which specifically interact with the promoter responsible for transcription start II (TSII), in particular those which specifically influence transcription, in particular those which reduce them.
- TSII promoter responsible for transcription start II
- in comparison to the promoter responsible for transcription start I (TSI) means a difference by at least a factor of 5, preferably by at least a factor of 10 and particularly preferably by at least a factor of 25.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00931087A EP1206279A1 (de) | 1999-05-07 | 2000-04-28 | Verfahren zur behandlung von tnf-rezeptor typ-2 vermittelten krankheiten |
AU49146/00A AU4914600A (en) | 1999-05-07 | 2000-04-28 | Method for treating tnf-receptor type-2-induced diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19922444.7 | 1999-05-07 | ||
DE19922444A DE19922444A1 (de) | 1999-05-07 | 1999-05-07 | Verfahren zur Behandlung von TNF-Rezeptor vermittelten Krankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000067790A1 true WO2000067790A1 (de) | 2000-11-16 |
Family
ID=7908195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/003866 WO2000067790A1 (de) | 1999-05-07 | 2000-04-28 | Verfahren zur behandlung von tnf-rezeptor typ-2 vermittelten krankheiten |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1206279A1 (de) |
AU (1) | AU4914600A (de) |
DE (1) | DE19922444A1 (de) |
WO (1) | WO2000067790A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7915225B2 (en) | 1999-04-19 | 2011-03-29 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741667A (en) * | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
-
1999
- 1999-05-07 DE DE19922444A patent/DE19922444A1/de not_active Withdrawn
-
2000
- 2000-04-28 AU AU49146/00A patent/AU4914600A/en not_active Abandoned
- 2000-04-28 WO PCT/EP2000/003866 patent/WO2000067790A1/de not_active Application Discontinuation
- 2000-04-28 EP EP00931087A patent/EP1206279A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741667A (en) * | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
Non-Patent Citations (8)
Title |
---|
C. SEITZ ET AL.: "Isolation and functional characterization of the mouse p75 TNF receptor promoter.", GENOMICS, vol. 48, no. 1, 15 February 1998 (1998-02-15), San Diego, CA, VSA, pages 111 - 116, XP000929452 * |
D. BUTLER ET AL.: "p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts.", EUROPEAN CYTOKINE NETWORK, vol. 5, no. 5, September 1994 (1994-09-01), Montrouge, pages 441 - 448, XP000929419 * |
H. OHARA ET AL.: "Effect of gene transfer of tumor necrosis factor receptors into human lung carcinoma cell line.", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 89, no. 5, May 1998 (1998-05-01), Japan, pages 589 - 595, XP000929421 * |
H. SONG ET AL.: "Association of a RING finger protein wuth the cytoplasmic domain of the human type-2 tumour necrosis factor receptor.", BIOCHEMICAL JOURNAL, vol. 309, no. 3, 1 August 1995 (1995-08-01), London, Grossbritannien, pages 825 - 829, XP000929418 * |
J. BIGDA ET AL.: "TNF receptors - How they function and interact.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 45, no. 4, 1997, Polen, pages 263 - 270, XP002089651 * |
M. LEWIS ET AL.: "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 88, no. 7, 1 April 1991 (1991-04-01), Washington, DC, VSA, pages 2830 - 2834, XP002143360 * |
R. BRINK ET AL.: "Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappaB activation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 7, 13 February 1998 (1998-02-13), Baltimore, MD, VSA, pages 4129 - 4134, XP002143359 * |
Y. SHEN ET AL.: "Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 6, 7 February 1997 (1997-02-07), Baltimore, MD, VSA, pages 3550 - 3553, XP002143358 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7915225B2 (en) | 1999-04-19 | 2011-03-29 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US8119605B2 (en) | 1999-04-19 | 2012-02-21 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US8722631B2 (en) | 1999-04-19 | 2014-05-13 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
Also Published As
Publication number | Publication date |
---|---|
DE19922444A1 (de) | 2000-11-09 |
EP1206279A1 (de) | 2002-05-22 |
AU4914600A (en) | 2000-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abraham et al. | Correlations between immediate early gene induction and the persistence of long-term potentiation | |
DE69433309T3 (de) | Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase | |
Davies et al. | Expression patterns of the novel imprinted genes Nap1l5 and Peg13 and their non-imprinted host genes in the adult mouse brain | |
DE19824230A1 (de) | Neues Endometriose-assoziiertes Gen | |
EP1453531B1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
Sikora et al. | Studies of the relationship between cell proliferation and cell death. III. AP-1 DNA-binding activity during concanavalin A-induced proliferation or dexamethasone-induced apoptosis of rat thymocytes | |
DE10215321A1 (de) | Trp-p8 Splice Varianten und regulatorische RNA | |
WO2000067790A1 (de) | Verfahren zur behandlung von tnf-rezeptor typ-2 vermittelten krankheiten | |
EP0614974A2 (de) | Knochenassoziiertes, Transkriptionskontrollfaktor-ähnliches Protein und Verfahren zu dessen Herstellung | |
EP0986642B1 (de) | Hbv-gerichtete antisense-nukleinsäuren | |
Chaudhary et al. | Induction of early growth response-1 gene by interleukin-1β and tumor necrosis factor-α in normal human bone marrow stromal and osteoblastic cells: regulation by a protein kinase C inhibitor | |
WO2004029631A2 (de) | Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon | |
DE10021834A1 (de) | mRNA Moleküle zur Verwendung als Indikatoren für den Aktivierungs- und Funktionszustand von T-Lymphozyten | |
DE60311097T2 (de) | Promotor sequenz des menschlichen 5-ht7 rezeptors | |
EP0941369B1 (de) | Dna zur abschätzung des progressionspotentials von zervixläsionen | |
WO2000039292A2 (de) | Antisense-oligonukleotid zur hemmung der expression des adhäsionsmoleküls very late antigen 4 (vla-4) in menschlichen zellen | |
EP1086220A2 (de) | Gdnf-kodierende dna, teile davon und gdnf-varianten | |
DE60117001T2 (de) | Nectin-3 proteine | |
DE102015119873A1 (de) | Neuer Tumormarker für das Rhabdomyosarkom | |
WO1999042477A2 (de) | Transporterprotein für saccharid-gekoppelte arzneimittel | |
DE4422259C2 (de) | Anti-Sinn-Oligonukleotide zur Aromatase-Inhibierung | |
WO2005116201A1 (de) | TYROSINKINASE TNK ALS INHIBITOR FÜR DEN NUKLEÄREN TRANSKRIPTIONSFAKTOR KAPPA B (NFκB) | |
EP1049810A2 (de) | HEMMUNG DER DURCH MUTIERTES p53 VERURSACHTEN MODULATION VON DNA | |
DE19644501A1 (de) | GABA¶A¶-Rezeptoruntereinheit epsilon-verwandtes Protein | |
DE19906921A1 (de) | Neuronal-cell-survival-factor (NCSF) und seine Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000931087 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931087 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931087 Country of ref document: EP |